Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glucosaminic Acid SCHEMBL7642316 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL30955946 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL396940 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL13984380 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL17830012 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL13010965 | 1.00 | USP2 (1.00) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Glucosaminic Acid SCHEMBL27248833 | 0.96 | USP2 (0.91) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL812543 | 0.93 | USP2 (0.86) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL7148984 | 0.93 | USP2 (0.86) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Galactitol SCHEMBL9487119 | 0.85 | USP2 (0.73) | USP2SLCO1B1PDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| CN-119912365-A | Taurine refining process and application thereof | 江阴华昌食品添加剂有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240156877-A1 | COMPOSITIONS AND USES THEREFOR | MELCARE MEDICAL PTY LTD (AU) | 2024-05-16 | — | — | US | disclosed |
| EP-4368178-A1 | COMPOSITIONS OF HONEY AND GLUCONIC ACID AND USES THEREFOR | Melcare Medical Pty Ltd (AU) | 2024-05-15 | — | — | EP | disclosed |
| CN-118001410-A | Composition and use thereof | 麦尔凯亚医学股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11946092-B2 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-d-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2024-04-02 | — | — | US | disclosed |
| CN-114672522-B | Method for producing 2-keto-3-deoxy-D-gluconic acid by catalyzing N-acetyl-D-gluconolactone with double enzymes | 山东大学 | 2023-12-26 | — | — | CN | disclosed |
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230323409-A1 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | SHANDONG UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | USP2 319/4885SLCO1B1 1200/4885PDE4A 3611/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | USP2 867/4885SLCO1B1 3784/4885PDE4A 3486/4885 |
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ENTPD5, KLK3, GUSB | USP2 746/4885SLCO1B1 376/4885PDE4A 1246/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | USP2 633/4885SLCO1B1 1217/4885PDE4A 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.